{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:43:29Z","timestamp":1792205009382,"version":"4.4.0"},"reference-count":97,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The development of heterocyclic derivatives has progressed considerably over the past decades, and many new carbonic anhydrase inhibitors (CAIs) fall into this field. In particular, five-membered heterocyclic sulfonamides have been generally shown to be more effective inhibitors compared to six-membered rings ones. Despite the importance of oxygen and nitrogen five-membered heterocyclic aromatic rings in medicinal chemistry, the installation of sulfonamide moiety on such heterocycles has not received much attention. On the other hand, 1,3,4-thiadiazole\/thiadiazoline ring-bearing sulfonamides are the scaffolds which have been widely used in a variety of pharmaceutically important CAIs such as acetazolamide, metazolamide and their many derivatives obtained by using the tail approach. Here, we reviewed the field focusing on the diverse biological activities of these CAIs, such as antiglaucoma, antiepileptic, antitumor and antiinfective properties. This review highlights developments involving five-membered heterocyclic sulfonamides over the last years, with a focus on their pharmacological\/clinical applications.<\/jats:p>","DOI":"10.3390\/molecules28073220","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T01:39:26Z","timestamp":1680658766000},"page":"3220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Five-Membered Heterocyclic Sulfonamides as Carbonic Anhydrase Inhibitors"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-7192","authenticated-orcid":false,"given":"Andrea","family":"Angeli","sequence":"first","affiliation":[{"name":"NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-9419","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Paoletti","sequence":"additional","affiliation":[{"name":"NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[{"name":"NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1042\/CS20210040","article-title":"Emerging role of carbonic anhydrase inhibitors","volume":"135","author":"Supuran","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23068","DOI":"10.1002\/anie.202103211","article-title":"Modulating the efficacy of carbonic anhydrase inhibitors through fluorine substitution","volume":"60","author":"Berrino","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2174\/138161208783877857","article-title":"Carbonic anhydrase activation and the drug design","volume":"14","author":"Temperini","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1042\/BCJ20160115","article-title":"Structure and function of carbonic anhydrases","volume":"473","author":"Supuran","year":"2016","journal-title":"Biochem. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/14756366.2021.1897802","article-title":"Activation of the \u03b2-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with amines and amino acids","volume":"36","author":"Angeli","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2018.01.003","article-title":"The \u03b3-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae is potently activated by amines and amino acids","volume":"77","author":"Angeli","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/14756366.2019.1571273","article-title":"Inhibition of \u03b1-, \u03b2-, \u03b3-, \u03b4-, \u03b6- and \u03b7-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine","volume":"34","author":"Angeli","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bioorg.2018.05.027","article-title":"The zinc\u2014But not cadmium\u2014Containing \u03b6-carbonic from the diatom Thalassiosira weissflogii is potently activated by amines and amino acids","volume":"80","author":"Angeli","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jensen, E.L., Receveur-Brechot, V., Hachemane, M., Wils, L., Barbier, P., Parsiegla, G., Gontero, B., and Launay, H. (2021). Structural contour map of the iota carbonic anhydrase from the diatom thalassiosira pseudonana using a multiprong approach. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168723"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/13543776.2018.1508453","article-title":"Carbonic anhydrase inhibitors as antitumor\/antimetastatic agents: A patent review (2008-2018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543776.2020.1811853","article-title":"Antibacterial carbonic anhydrase inhibitors: An update on the recent literature","volume":"30","author":"Supuran","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4155\/fmc.11.69","article-title":"Carbonic anhydrase inhibitors and activators for novel therapeutic applications","volume":"3","author":"Supuran","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.2174\/0929867325666180622120625","article-title":"State of the art on carbonic anhydrase modulators for biomedical purposes","volume":"26","author":"Bozdag","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/13543776.2019.1674285","article-title":"The management of glaucoma and macular degeneration","volume":"29","author":"Supuran","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113793","DOI":"10.1016\/j.ejmech.2021.113793","article-title":"Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action","volume":"225","author":"Tanini","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Angeli, A., Carta, F., Nocentini, A., Winum, J.Y., Zalubovskis, R., Akdemir, A., Onnis, V., Eldehna, W.M., Capasso, C., and Simone, G. (2020). Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites, 10.","DOI":"10.3390\/metabo10100412"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1080\/14756366.2022.2121393","article-title":"Anti-obesity carbonic anhydrase inhibitors: Challenges and opportunities","volume":"37","author":"Supuran","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/156802607780636726","article-title":"Carbonic anhydrase inhibitors as anticonvulsant agents","volume":"7","author":"Thiry","year":"2007","journal-title":"Curr. Top Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0021-9258(19)51331-X","article-title":"The inhibition of carbonic anhydrase by thiophene-2-sulfonamide and sulfanilamide","volume":"158","author":"Davenport","year":"1945","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1021\/ja01167a012","article-title":"Heterocyclic sulfonamides as carbonic anhydrase inhibitors","volume":"72","author":"Miller","year":"1950","journal-title":"J. Am. Chem. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1021\/ja01167a011","article-title":"The preparation of heterocyclic sulfonamides","volume":"72","author":"Roblin","year":"1950","journal-title":"J. Am. Chem. Soc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/jm00164a045","article-title":"Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides","volume":"33","author":"Graham","year":"1990","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/jid.1969.42","article-title":"The identification of contact allergens by animal assay. The guinea pig maximization test","volume":"52","author":"Magnusson","year":"1969","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1002\/slct.202101854","article-title":"A Practical method of N-Methylpyrrole disulfonamides synthesis: Computational studies, carbonic anhydrase inhibition and electrochemical DNA binding investigations","volume":"6","author":"Abas","year":"2021","journal-title":"ChemistrySelect"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1016\/j.bmc.2014.06.016","article-title":"Furazan and furoxan sulfonamides are strong \u03b1-carbonic anhydrase inhibitors and potential antiglaucoma agents","volume":"22","author":"Chegaev","year":"2014","journal-title":"Bioorganic Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jhet.149","article-title":"Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides","volume":"46","author":"Chegaev","year":"2009","journal-title":"J. Heterocycl. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.bmc.2017.02.018","article-title":"Human carbonic anhydrase inhibitory profile of mono- and bis-sulfonamides synthesized via a direct sulfochlorination of 3- and 4-(hetero)arylisoxazol-5-amine scaffolds","volume":"25","author":"Krasavin","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1527-3458.1998.tb00075.x","article-title":"Zonisamide: Pharmacology and clinical efficacy in epilepsy","volume":"4","author":"Masuda","year":"1998","journal-title":"CNS Drug Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(92)90087-A","article-title":"Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex","volume":"12","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","article-title":"Mechanisms of T-type calcium channel blockade by zonisamide","volume":"5","author":"Kito","year":"1996","journal-title":"Seizure"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","volume":"116","author":"Ueda","year":"2003","journal-title":"Mol. Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","article-title":"Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies","volume":"15","author":"Menchise","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/jm031057+","article-title":"Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides","volume":"47","author":"Vullo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1517\/13543776.2013.790957","article-title":"Antiobesity carbonic anhydrase inhibitors: A literature and patent review","volume":"23","author":"Scozzafava","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1358\/dot.2005.41.9.921095","article-title":"Zonisamide: Review of its use in epilepsy therapy","volume":"41","author":"Zareba","year":"2005","journal-title":"Drugs Today"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1021\/jm00114a020","article-title":"Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides","volume":"34","author":"Shepard","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1021\/jm00110a008","article-title":"New isomeric classes of topically active ocular hypotensive carbonic anhydrase inhibitors: 5-substituted thieno[2,3-b]thiophene-2-sulfonamides and 5-substituted thieno[3,2-b]thiophene-2-sulfonamides","volume":"34","author":"Prugh","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1016\/j.bmc.2013.06.041","article-title":"5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: Solution and X-ray crystallographic studies","volume":"21","author":"Leitans","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bmc.2016.11.045","article-title":"5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations","volume":"25","author":"Ivanova","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2015.06.022","article-title":"Probing the \u2018bipolar\u2019 nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms","volume":"101","author":"Krasavin","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.bmc.2017.06.054","article-title":"1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads","volume":"25","author":"Ferraroni","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14756366.2022.2056733","article-title":"5-(Sulfamoyl)thien-2-yl 1,3-oxazole inhibitors of carbonic anhydrase II with hydrophilic periphery","volume":"37","author":"Kalinin","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00253-022-11969-0","article-title":"Biological activity of oxadiazole and thiadiazole derivatives","volume":"106","author":"Atmaram","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/13543776.2022.2067477","article-title":"Anti-viral activity of thiazole derivatives: An updated patent review","volume":"32","author":"Farghaly","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","article-title":"Discovery, chemistry, and preclinical development of pritelivir, a novel treatment option for acyclovir-resistant Herpes simplex virus infections","volume":"65","author":"Birkmann","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/acs.jmedchem.7b00183","article-title":"Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action","volume":"60","author":"Carta","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-4835(92)90094-9","article-title":"Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide","volume":"55","author":"Maren","year":"1992","journal-title":"Exp. Eye Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1021\/jm00131a011","article-title":"Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide","volume":"32","author":"Woltersdorf","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/138161208783877866","article-title":"The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents","volume":"14","author":"Mincione","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bmc.2015.02.027","article-title":"A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects","volume":"23","author":"Carta","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Micheli, L., Testai, L., Angeli, A., Carrino, D., Pacini, A., Margiotta, F., Flori, L., Supuran, C.T., Calderone, V., and Ghelardini, C. (2022). Inhibitors of mitochondrial human carbonic anhydrases VA and VB as a therapeutic strategy against paclitaxel-induced neuropathic pain in mice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116229"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14737175.2016.1193009","article-title":"Carbonic anhydrase inhibition and the management of neuropathic pain","volume":"16","author":"Supuran","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cmdc.201200355","article-title":"Thiadiazole-a promising structure in medicinal chemistry","volume":"8","author":"Li","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/13543776.2017.1272575","article-title":"Thiadiazole inhibitors: A patent review","volume":"27","author":"Dawood","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2146\/ajhp170279","article-title":"Evaluating off-label uses of acetazolamide","volume":"75","author":"Elefritz","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14756366.2021.1991336","article-title":"Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae","volume":"37","author":"Abutaleb","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/14756366.2021.2004592","article-title":"Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines","volume":"37","author":"Mussi","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.bmcl.2004.01.096","article-title":"Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide","volume":"14","author":"Abbate","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/pro.5560071201","article-title":"Structural analysis of inhibitor binding to human carbonic anhydrase II","volume":"7","author":"Zeitlin","year":"1998","journal-title":"Protein Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0223-5234(98)80042-1","article-title":"Carbonic anhydrase inhibitors\u2014Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives","volume":"33","author":"Supuran","year":"1998","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","first-page":"1549","article-title":"A carbonic anhydrase inhibitor as a potential modulator of cancer therapies","volume":"13","author":"Teicher","year":"1993","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0968-0896(00)00288-1","article-title":"Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?","volume":"9","author":"Supuran","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/17460441.2015.1038235","article-title":"Designing carbonic anhydrase inhibitors for the treatment of breast cancer","volume":"10","author":"Supuran","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1021\/jm031079w","article-title":"Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX","volume":"47","author":"Casey","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bmcl.2004.10.070","article-title":"Carbonic anhydrase inhibitors. Novel sulfanilamide\/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX","volume":"15","author":"Turkmen","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1021\/jm9900523","article-title":"Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic\/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring?","volume":"42","author":"Scozzafava","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bmc.2013.11.016","article-title":"Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies","volume":"22","author":"Bozdag","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"111642","DOI":"10.1016\/j.ejmech.2019.111642","article-title":"From random to rational: A discovery approach to selective subnanomolar inhibitors of human carbonic anhydrase IV based on the Castagnoli-Cushman multicomponent reaction","volume":"182","author":"Kalinin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17460441.2013.795145","article-title":"Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors","volume":"8","author":"Alterio","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1021\/jm501798g","article-title":"Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site","volume":"58","author":"Tanpure","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1021\/acs.jmedchem.2c00982","article-title":"Development of hydrogen sulfide-releasing carbonic anhydrases IX- and XII-selective inhibitors with enhanced antihyperalgesic action in a rat model of arthritis","volume":"65","author":"Bonardi","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"112897","DOI":"10.1016\/j.ejmech.2020.112897","article-title":"Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: Synthesis, biological and molecular dynamics analysis","volume":"209","author":"Abdelrahman","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7422","DOI":"10.1021\/acs.jmedchem.0c00733","article-title":"Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: Improving ligand\/isoform matching and selectivity of action","volume":"63","author":"Bonardi","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/14756366.2022.2053526","article-title":"The three-tails approach as a new strategy to improve selectivity of action of sulphonamide inhibitors against tumour-associated carbonic anhydrase IX and XII","volume":"37","author":"Bonardi","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nchem.2158","article-title":"Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation","volume":"7","author":"Wichert","year":"2015","journal-title":"Nat. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1158\/1078-0432.CCR-17-3457","article-title":"Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2","volume":"24","author":"Cazzamalli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"127255","DOI":"10.1016\/j.bmcl.2020.127255","article-title":"Synthesis and evaluation of indium-111-labeled imidazothiadiazole sulfonamide derivative for single photon emission computed tomography imaging targeting carbonic anhydrase-IX","volume":"30","author":"Iikuni","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bmcl.2018.01.060","article-title":"Acetazolamide-based [18F]-PET tracer: In vivo validation of carbonic anhydrase IX as a sole target for imaging of CA-IX expressing hypoxic solid tumors","volume":"28","author":"More","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nucmedbio.2020.11.008","article-title":"Synthesis and evaluation of 68Ga-labeled imidazothiadiazole sulfonamide derivatives for PET imaging of carbonic anhydrase-IX","volume":"93","author":"Nakashima","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"127596","DOI":"10.1016\/j.bmcl.2020.127596","article-title":"Synthesis and evaluation of novel technetium-99m-hydroxamamide complex based on imidazothiadiazole sulfonamide targeting carbonic anhydrase-IX for tumor imaging","volume":"30","author":"Iikuni","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2174\/1381612823666170209154745","article-title":"In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens","volume":"23","author":"Younis","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_87","first-page":"204","article-title":"Inhibition of carbonic anhydrase in neisseria: Effects on enzyme activity and growth","volume":"3","author":"Sanders","year":"1967","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.1021\/acs.jmedchem.0c00734","article-title":"Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant Enterococcus","volume":"63","author":"Kaur","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/acsinfecdis.1c00055","article-title":"Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae","volume":"7","author":"Hewitt","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1021\/acsmedchemlett.2c00471","article-title":"Structural characterization of thiadiazolesulfonamide inhibitors bound to neisseria gonorrhoeae \u03b1-carbonic anhydrase","volume":"14","author":"Marapaka","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/106002809603000515","article-title":"Acetazolamide in the treatment of seizures","volume":"30","author":"Reiss","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1021\/acs.jmedchem.0c01889","article-title":"discovery of potent carbonic anhydrase inhibitors as effective anticonvulsant agents: Drug design, synthesis, and in vitro and in vivo investigations","volume":"64","author":"Mishra","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0014-827X(99)00096-8","article-title":"Anticonvulsant activity of analogues of acetazolamide","volume":"54","author":"Pedregosa","year":"1999","journal-title":"Farmaco"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm0109199","article-title":"Carbonic anhydrase inhibitors: Anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties","volume":"45","author":"Masereel","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cmdc.201900703","article-title":"5-[2-(N-(Substituted phenyl)acetamide)]amino-1,3,4-thiadiazole-2-sulfonamides as selective carbonic anhydrase II Inhibitors with neuroprotective effects","volume":"15","author":"Jiang","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1016\/j.bmc.2009.06.006","article-title":"Carbonic anhydrase inhibitors. Aromatic\/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB","volume":"17","author":"Innocenti","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.bmcl.2011.01.050","article-title":"(R)-\/(S)-10-camphorsulfonyl-substituted aromatic\/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases","volume":"21","author":"Maresca","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/7\/3220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:05Z","timestamp":1760123405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/7\/3220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["molecules28073220"],"URL":"https:\/\/doi.org\/10.3390\/molecules28073220","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}